Alkermes plc (NASDAQ:ALKS) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 45.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 217,980 shares of the company's stock after purchasing an additional 68,487 shares during the period. BNP Paribas Financial Markets owned about 0.13% of Alkermes worth $6,269,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Renaissance Technologies LLC lifted its stake in shares of Alkermes by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock valued at $157,568,000 after buying an additional 57,697 shares during the period. American Century Companies Inc. raised its holdings in Alkermes by 6.5% in the 4th quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock valued at $99,242,000 after acquiring an additional 209,740 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Alkermes by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after purchasing an additional 128,701 shares during the period. Avoro Capital Advisors LLC acquired a new stake in shares of Alkermes during the fourth quarter worth $70,462,000. Finally, Loomis Sayles & Co. L P grew its position in shares of Alkermes by 22.3% in the fourth quarter. Loomis Sayles & Co. L P now owns 2,302,905 shares of the company's stock valued at $66,232,000 after purchasing an additional 419,969 shares during the period. 95.21% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on ALKS. UBS Group reiterated a "sector perform" rating on shares of Alkermes in a research report on Monday, April 28th. Royal Bank of Canada upped their price target on shares of Alkermes from $39.00 to $40.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. Robert W. Baird increased their target price on Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group boosted their target price on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Alkermes currently has an average rating of "Moderate Buy" and a consensus price target of $38.33.

Alkermes Price Performance

ALKS traded up $0.21 during trading hours on Friday, reaching $31.42. 992,676 shares of the stock traded hands, compared to its average volume of 1,763,351. Alkermes plc has a fifty-two week low of $22.90 and a fifty-two week high of $36.45. The company has a market cap of $5.18 billion, a price-to-earnings ratio of 14.48, a PEG ratio of 2.20 and a beta of 0.51. The firm's fifty day simple moving average is $30.62 and its two-hundred day simple moving average is $30.64.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). The business had revenue of $306.51 million during the quarter, compared to analysts' expectations of $307.53 million. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The company's revenue for the quarter was down 12.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 EPS. On average, research analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.